In this short presentation Prof. Hoeper explains whether riociguat is an option in PAH treatment for patients with an insufficient response to PDE-5 inhibitors.
Is switching treatments from PDE5 inhibitors to riociguat an option in patients with PAH?
Department of Pneumology, Medical School Hanover
50mins - Expert presentations By Centers for Disease Control and Prevention
Zika Virus—What Clinicians Need to Know
Experts from the CDC present a comprehensive overview: Zika Virus-What Clinicians Need to Know, and provide responses to selected questions
9mins - Expert presentations By Vicky Tittle
Dr Vicky Tittle, from 56 Dean Street in London, UK, reviews the reasons to test for HIV, when and how to test and which key populations should receive testing. Specific focus is placed on British guidelines for HIV testing and importance to conduct key initial investigations.
13mins - Expert presentations By Professor David Livermore
Future developments in antimicrobial agents
Professor David Livermore highlights increasing resistance and the major bacterial challenges we face. Beta-lactams, the most widely used antibiotic are losing their efficacy. However, there is hope for antimicorbial agents. Cefiderocol, murepavadin and gepotidacin/zoliflodacin all show promise in replacing spent antibiotics. Further, non-antibiotic approaches and improved molecular diagnostics, while not currently comprehensive, could revolutionise the field.